loading
Schlusskurs vom Vortag:
$3.19
Offen:
$3.09
24-Stunden-Volumen:
28,899
Relative Volume:
0.03
Marktkapitalisierung:
$4.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.28M
KGV:
-4.9385
EPS:
-0.65
Netto-Cashflow:
$-13.75M
1W Leistung:
-3.94%
1M Leistung:
-27.79%
6M Leistung:
-52.00%
1J Leistung:
-50.78%
1-Tages-Spanne:
Value
$3.055
$3.32
1-Wochen-Bereich:
Value
$2.92
$3.42
52-Wochen-Spanne:
Value
$2.92
$17.40

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name
Firmenname
Pasithea Therapeutics Corp
Name
Telefon
(818) 422-6172
Name
Adresse
2110 NARCISSUS CT, VENICE
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-11
Name
Neueste SEC-Einreichungen
Name
KTTA's Discussions on Twitter

Vergleichen Sie KTTA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
KTTA 3.20 4.04M 0 -16.28M -13.75M -0.65
VRTX 449.09 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.38 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 587.39 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.66 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.77 24.89B 3.30B -501.07M 1.03B 11.54

Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten

pulisher
Nov 20, 2024

Pasithea Therapeutics Announces Positive Safety Review - GlobeNewswire

Nov 20, 2024
pulisher
Nov 20, 2024

Pasithea's PAS-004 Drug Shows Strong Safety Profile in Phase 1 Trial, Zero Toxicity Issues | KTTA Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 16, 2024

Pasithea Therapeutics (NASDAQ:KTTA) Shares Up 2.4% – Still a Buy? - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

KTTA stock touches 52-week low at $3.19 amid market challenges By Investing.com - Investing.com South Africa

Nov 15, 2024
pulisher
Nov 15, 2024

KTTA stock touches 52-week low at $3.19 amid market challenges - Investing.com UK

Nov 15, 2024
pulisher
Nov 14, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeuti - GuruFocus.com

Nov 14, 2024
pulisher
Nov 09, 2024

KTTA stock touches 52-week low at $3.4 amid market challenges - Investing.com Australia

Nov 09, 2024
pulisher
Nov 04, 2024

Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA) - The Wall Street Transcript

Nov 04, 2024
pulisher
Oct 26, 2024

KTTA stock touches 52-week low at $3.6 amid market challenges - Investing.com Australia

Oct 26, 2024
pulisher
Oct 25, 2024

KTTA stock touches 52-week low at $3.6 amid market challenges By Investing.com - Investing.com South Africa

Oct 25, 2024
pulisher
Oct 20, 2024

pasithea therapeutics corp Earnings dates - RTTNews

Oct 20, 2024
pulisher
Oct 07, 2024

(KTTA) Investment Analysis - Stock Traders Daily

Oct 07, 2024
pulisher
Oct 02, 2024

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Act - GuruFocus.com

Oct 02, 2024
pulisher
Sep 30, 2024

Was there any good news for Pasithea Therapeutics Corp (KTTA) stock in the last session? - US Post News

Sep 30, 2024
pulisher
Sep 27, 2024

Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com

Sep 27, 2024
pulisher
Sep 27, 2024

Market cap of Pasithea Therapeutics Corp [KTTA] reaches 6.08M – now what? - The DBT News

Sep 27, 2024
pulisher
Sep 27, 2024

PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors - OncLive

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Gains After Private Placement - DRP Journal

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics drops 19% on $5M private placement - MSN

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com

Sep 27, 2024
pulisher
Sep 27, 2024

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times

Sep 27, 2024
pulisher
Sep 26, 2024

Grid Battery Metals Inc. (TSXV:CELL) (OTCQB:EVKRF) Stock Gains Momentum: Is It Sustainable? - DRP Journal

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

Technical Explosions: DUO, KTTA, TBIO, GOTUWatch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum! - openPR

Sep 26, 2024
pulisher
Sep 26, 2024

Schwab Splitting Shares for Two-Thirds of ETF Lineup - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials - Investorideas.com newswire

Sep 26, 2024
pulisher
Sep 26, 2024

Dow Surges Over 250 Points; Accenture Earnings Top Views - Benzinga

Sep 26, 2024
pulisher
Sep 26, 2024

Stocks Stay Higher With Tech Still Driving Gains: Markets Wrap - Yahoo Finance

Sep 26, 2024
pulisher
Sep 26, 2024

Why XPeng Stock Spiked Higher Today - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Why Is Pasithea Therapeutics Stock Surging On Thursday? - AOL

Sep 26, 2024
pulisher
Sep 26, 2024

KTTA’s price-to-free cash flow ratio: What it means for investors - US Post News

Sep 26, 2024
pulisher
Sep 26, 2024

Crude Oil Down Over 2%; US Initial Jobless Claims Fall - Benzinga

Sep 26, 2024
pulisher
Sep 26, 2024

English cricket ‘disconnected from reality’ in valuation of the Hundred - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Shares Move Higher After Positive Data for Cancer Treatment - MarketWatch

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea reports positive early data on cancer drug PAS-004 - Investing.com India

Sep 26, 2024
pulisher
Sep 26, 2024

Visa agrees to buy AI-focused enterprise tech firm Featurespace - Yahoo! Voices

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics (KTTA) Sees Strong Pre-Market Gains - Stocks Telegraph

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics rises on positive early-stage data from cancer drug - XM

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics : Investor Presentation - Marketscreener.com

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), And Preliminary Efficacy Data From Its Phase 1 Clinical T... - MENAFN.COM

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004 - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics (KTTA) Reports Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from Phase 1 Trial of PAS-004 - StreetInsider.com

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, - GlobeNewswire

Sep 26, 2024
pulisher
Sep 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - StockTitan

Sep 26, 2024
pulisher
Sep 25, 2024

Factbox-OpenAI key personnel changes - Yahoo! Voices

Sep 25, 2024
pulisher
Sep 25, 2024

Why Viking Therapeutics Stock Was So Healthy on Wednesday - Yahoo Finance

Sep 25, 2024
pulisher
Sep 25, 2024

Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding - Marketscreener.com

Sep 25, 2024
pulisher
Sep 25, 2024

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance

Sep 25, 2024
pulisher
Sep 25, 2024

Capstan Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Sep 25, 2024
pulisher
Sep 23, 2024

BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC - OncLive

Sep 23, 2024
pulisher
Sep 21, 2024

The OncFive: Top Oncology Articles for the Week of 9/15 - OncLive

Sep 21, 2024

Finanzdaten der Pasithea Therapeutics Corp-Aktie (KTTA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):